Design and synthesis of lipid-coupled inositol 1,2,3,4,5,6-hexakisphosphate derivatives exhibiting high-affinity binding for the HIV-1 MA domainElectronic supplementary information (ESI) available. See DOI: 10.1039/c4ob00350k
The precursor of Gag protein (Pr55 Gag ) of human immunodeficiency virus, the principal structural component required for virus assembly, is known to bind d - myo -phosphatidylinositol 4,5-bisphosphate (PIP 2 ). The N-terminus of Pr55 Gag , the MA domain, plays a critical role in the binding of Pr55...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Journal Article |
Language | English |
Published |
18.06.2014
|
Online Access | Get full text |
Cover
Loading…
Summary: | The precursor of Gag protein (Pr55
Gag
) of human immunodeficiency virus, the principal structural component required for virus assembly, is known to bind
d
-
myo
-phosphatidylinositol 4,5-bisphosphate (PIP
2
). The N-terminus of Pr55
Gag
, the MA domain, plays a critical role in the binding of Pr55
Gag
to the plasma membrane. Herein, we designed and synthesized
myo
-phosphatidylinositol 2,3,4,5,6-pentakisphosphate (PIP
5
) derivatives comprising highly phosphorylated inositol and variously modified diacylglycerol to examine the MA-binding properties. The inositol moiety was synthesized starting with
myo
-inositol and assembled with a hydrophobic glycerol moiety through a phosphate linkage. The
K
d
value for MA-binding of the PIP
5
derivative
2
(
K
d
= 0.25 M) was the lowest (
i.e.
, highest affinity) of all derivatives,
i.e.
, 70-fold lower than the
K
d
for the PIP
2
derivative
1
(
K
d
= 16.9 M) and 100-fold lower than the
K
d
for IP
6
(
K
d
= 25.7 M), suggesting the possibility that the PIP
5
derivative blocks Pr55
Gag
membrane binding by competing with PIP
2
in MA-binding.
Lipid-coupled inositol 1,2,3,4,5,6-hexakisphosphate binds to HIV-1 MA tightly through both electrostatic and hydrophobic interactions. |
---|---|
Bibliography: | 10.1039/c4ob00350k Electronic supplementary information (ESI) available. See DOI |
ISSN: | 1477-0520 1477-0539 |
DOI: | 10.1039/c4ob00350k |